This review examines the benefits and risks of adding exenatide twice daily, a glucagon-like peptide 1 (GLP-1) receptor agonist, in patients with type 2 diabetes who are currently treated with basal insulin, but have failed to reach their glycaemic goals. This evidence concerns the gene INS and type 2 diabetes mellitus.